JP7595061B2 - 抗タウ抗体およびその使用 - Google Patents

抗タウ抗体およびその使用 Download PDF

Info

Publication number
JP7595061B2
JP7595061B2 JP2022503414A JP2022503414A JP7595061B2 JP 7595061 B2 JP7595061 B2 JP 7595061B2 JP 2022503414 A JP2022503414 A JP 2022503414A JP 2022503414 A JP2022503414 A JP 2022503414A JP 7595061 B2 JP7595061 B2 JP 7595061B2
Authority
JP
Japan
Prior art keywords
antibody
tau
seq
amino acid
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022503414A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022541539A5 (enExample
JP2022541539A (ja
Inventor
ユン，スン－ヨン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Adel inc
Original Assignee
Adel inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adel inc filed Critical Adel inc
Publication of JP2022541539A publication Critical patent/JP2022541539A/ja
Publication of JP2022541539A5 publication Critical patent/JP2022541539A5/ja
Application granted granted Critical
Publication of JP7595061B2 publication Critical patent/JP7595061B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Mycology (AREA)
JP2022503414A 2019-07-15 2020-07-13 抗タウ抗体およびその使用 Active JP7595061B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR10-2019-0085233 2019-07-15
KR20190085233 2019-07-15
PCT/KR2020/009207 WO2021010712A1 (ko) 2019-07-15 2020-07-13 항-타우 항체 및 이의 용도

Publications (3)

Publication Number Publication Date
JP2022541539A JP2022541539A (ja) 2022-09-26
JP2022541539A5 JP2022541539A5 (enExample) 2023-07-24
JP7595061B2 true JP7595061B2 (ja) 2024-12-05

Family

ID=74088428

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022503414A Active JP7595061B2 (ja) 2019-07-15 2020-07-13 抗タウ抗体およびその使用

Country Status (16)

Country Link
US (1) US20220204601A1 (enExample)
EP (1) EP4001305B1 (enExample)
JP (1) JP7595061B2 (enExample)
KR (1) KR102196840B1 (enExample)
CN (1) CN114430744B (enExample)
AU (1) AU2020313751A1 (enExample)
BR (1) BR112022000719A2 (enExample)
CA (1) CA3143811A1 (enExample)
CL (1) CL2022000087A1 (enExample)
GB (1) GB2600599B (enExample)
IL (1) IL289813A (enExample)
MX (1) MX2022000603A (enExample)
MY (1) MY207132A (enExample)
PH (1) PH12022550106A1 (enExample)
WO (1) WO2021010712A1 (enExample)
ZA (1) ZA202200724B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014165271A2 (en) 2013-03-13 2014-10-09 Neotope Biosciences Limited Tau immunotherapy
MX2018013384A (es) 2016-05-02 2019-02-28 Prothena Biosciences Ltd Anticuerpos que reconocen tau.
EP3452507B1 (en) 2016-05-02 2022-10-19 Prothena Biosciences Limited Tau immunotherapy
SG11201910066QA (en) 2017-05-02 2019-11-28 Prothena Biosciences Ltd Antibodies recognizing tau
TWI859197B (zh) 2019-03-03 2024-10-21 愛爾蘭商普羅帝納生物科學公司 識別ｔａｕ之抗體
WO2023039456A1 (en) * 2021-09-09 2023-03-16 The University Of North Carolina At Chapel Hill Monoclonal antibodies targeting acetylated tau and methods of use thereof
EP4405680A1 (en) 2021-09-20 2024-07-31 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods for improving the efficacy of hdac inhibitor therapy and predicting the response to treatment with hdac inhibitor
KR20250010000A (ko) * 2022-05-27 2025-01-20 주식회사 진큐어 신규 펩타이드 및 그의 용도
CN115724967A (zh) * 2022-09-21 2023-03-03 天津鸿宇泰生物科技有限公司 一种识别Tau蛋白N端区域的单克隆抗体及其应用
JP2025540336A (ja) * 2022-12-08 2025-12-11 アデル，インク 抗タウ抗体及びペプチドを含む融合体とその用途
WO2024133723A1 (en) 2022-12-22 2024-06-27 Institut National de la Santé et de la Recherche Médicale Methods for decreasing therapeutic acquired resistance to chemotherapy and/or radiotherapy
CN116716352A (zh) * 2023-05-16 2023-09-08 深圳湾实验室 Tau蛋白聚集的细胞模型、其构建方法及应用
CN116693682B (zh) * 2023-06-02 2024-04-19 涌源合生科技(深圳)有限公司 抗Tau蛋白抗体及其制备方法和用途
CN116948025B (zh) * 2023-09-14 2024-04-02 北京凯祥弘康生物科技有限公司 一种抗Tau蛋白的抗体

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130251731A1 (en) 2012-03-22 2013-09-26 The Trustees Of The University Of Pennsylvania Tau Acetylation in the Pathogenesis of Alzheimers Disease and Other Related Tauopathies
JP2015530971A (ja) 2012-07-03 2015-10-29 ワシントン・ユニバーシティＷａｓｈｉｎｇｔｏｎ Ｕｎｉｖｅｒｓｉｔｙ タウに対する抗体

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2869438C (en) * 2012-04-05 2021-08-17 Ac Immune S.A. Humanized tau antibody
TWI734975B (zh) * 2014-06-27 2021-08-01 美商Ｃ２Ｎ醫療診斷有限責任公司 人類化抗-tau抗體
AR103713A1 (es) * 2015-02-26 2017-05-31 Lilly Co Eli Anticuerpos contra tau y sus usos
WO2018106889A1 (en) * 2016-12-09 2018-06-14 Cogwellin L.L.C. Diagnosis of alzheimer's disease
WO2018117647A1 (ko) * 2016-12-21 2018-06-28 주식회사 아델 변이된 타우 단백질 단편 및 이의 용도

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130251731A1 (en) 2012-03-22 2013-09-26 The Trustees Of The University Of Pennsylvania Tau Acetylation in the Pathogenesis of Alzheimers Disease and Other Related Tauopathies
JP2015530971A (ja) 2012-07-03 2015-10-29 ワシントン・ユニバーシティＷａｓｈｉｎｇｔｏｎ Ｕｎｉｖｅｒｓｉｔｙ タウに対する抗体

Also Published As

Publication number Publication date
IL289813A (en) 2022-03-01
CN114430744A (zh) 2022-05-03
MY207132A (en) 2025-01-31
EP4001305A1 (en) 2022-05-25
GB202201160D0 (en) 2022-03-16
GB2600599B (en) 2025-05-21
WO2021010712A1 (ko) 2021-01-21
CA3143811A1 (en) 2021-01-21
JP2022541539A (ja) 2022-09-26
TW202116801A (zh) 2021-05-01
CN114430744B (zh) 2024-06-21
AU2020313751A1 (en) 2022-02-10
US20220204601A1 (en) 2022-06-30
KR102196840B1 (ko) 2020-12-30
BR112022000719A2 (pt) 2022-03-29
EP4001305B1 (en) 2026-07-01
EP4001305A9 (en) 2023-05-24
ZA202200724B (en) 2026-04-29
GB2600599A8 (en) 2024-12-25
PH12022550106A1 (en) 2022-11-21
EP4001305A4 (en) 2022-10-12
CL2022000087A1 (es) 2023-03-10
GB2600599A (en) 2022-05-04
MX2022000603A (es) 2022-05-20

Similar Documents

Publication Publication Date Title
US20220204601A1 (en) Anti-tau antibody and use of same
KR101591206B1 (ko) 치료적 특성을 갖는 베타 1-42 특이적인 단일클론성 항체
JP6884025B2 (ja) アルツハイマ病の治療および診断方法における使用のためのＮ末端切断型アミロイドβプロトフィブリル／オリゴマ
EP3160999B1 (en) Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
JP5765857B2 (ja) Ａβオリゴマーに特異的に結合する抗体およびその利用
JP6290212B2 (ja) タウオパチーの処置方法
CN104602708B (zh) 痴呆症治疗药或预防药
IL263530B2 (en) Antibodies specific for hyperphosphorylated tau and methods of use thereof
IL272615A (en) Human antibodies that detect alpha-synuclein, preparations containing them and their uses
JP6446443B2 (ja) タウオパチーの処置方法
JP2018139530A (ja) 認知症治療又は予防のためのヒト化抗体及びその製造方法、並びにそれを用いた認知症治療剤又は予防剤
JP7109467B2 (ja) タウに特異的に結合する結合分子
JPWO2009051220A1 (ja) Ａβオリゴマーに特異的に結合する抗体およびその利用
WO2023206609A1 (zh) 针对p-tau 217的抗体及其用途
US11434281B2 (en) Monoclonal antibodies targeting PHF1 and AT8 epitopes of human tau protein
JP2022528459A (ja) 融合構築物及びその使用
EP4458860A1 (en) Antibody specifically binding to asm, and use thereof
EP4399218A2 (en) Methods and materials to treat neurodegenerative disease
EA047253B1 (ru) Антитело к тау-белку и его применение
NZ738595A (en) Antibodies specific for hyperphosphorylated tau and methods of use thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230713

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230713

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240708

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240710

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241008

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20241119

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20241125

R150 Certificate of patent or registration of utility model

Ref document number: 7595061

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150